Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2503895 | 0.85 | TRPM8 (0.34) | GPR3ALOX5MEN1MAPTKMT2A | |
| SCHEMBL2504935 | 0.78 | SLC9A1 (0.30) | — | |
| SCHEMBL4099685 | 0.76 | GPR3 (0.40) | GPR3ALOX5PRNPRXFP1ALDH1A1 | |
| SCHEMBL4099681 | 0.76 | GPR3 (0.40) | GPR3ALOX5PRNPRXFP1ALDH1A1 | |
| SCHEMBL13813423 | 0.74 | GPR3 (0.33) | GPR3ALOX5MEN1MAPTKMT2A | |
| SCHEMBL4099239 | 0.74 | ALOX5 (0.35) | GPR3ALOX5PRNPRXFP1 | |
| SCHEMBL4099235 | 0.74 | ALOX5 (0.35) | GPR3ALOX5PRNPRXFP1 | |
| SCHEMBL13041056 | 0.73 | ALOX5 (0.41) | ALOX5MAPTALDH1A1 | |
| SCHEMBL3742330 | 0.73 | ALOX5 (0.41) | ALOX5MAPTALDH1A1 | |
| SCHEMBL12425595 | 0.71 | GPR3 (0.46) | GPR3ALOX5MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | GPR3 4277/4885ALOX5 2681/4885MEN1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.